Advisory Panel Urges Randomized Trials For New Prostate Cancer Treatments
This article was originally published in The Gray Sheet
Executive Summary
Developers of targeted prostate cancer treatments should conduct randomized clinical trials with "watchful waiting" as a control, according to FDA's Gastroenterology and Urology Devices panel